GLP-1 medication with standard therapy for rectal cancer
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests whether adding a GLP-1 receptor agonist (a medicine used for diabetes and weight loss) to standard chemo-radiation before surgery can improve outcomes for overweight patients with rectal cancer. It aims to see if the medication helps shrink the tumor and improves treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that has not spread to other parts of the body (confirmed by biopsy).
- Your body mass index (BMI) is 25 or higher (considered overweight).
- The rectal tumor is large enough or has features on MRI that make it high-risk, but it is not stage T4.
- Your kidneys, liver, and blood counts are within safe limits.
- You have not had chemotherapy or radiation for this cancer before.
- You have not used weight-loss medications or had weight-loss surgery before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding the immunotherapy drug tislelizumab to standard total neoadjuvant treatment (chemotherapy and radiation before surgery) can improve outcomes for people with locally advanced rectal cancer. The goal is to see if the combination helps shrink the tumor more than standard treatment alone.
This trial tests a short course of radiation with chemotherapy, targeted therapy, and immunotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
This trial tests adding immunotherapy to standard radiation and chemotherapy for patients with locally advanced rectal cancer. The goal is to see if a personalized approach improves outcomes while sparing more normal tissue.
This trial tests a combination of radiation, chemotherapy (CAPOX), and immunotherapy (iparomlimab and tuvonralimab) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with chemotherapy and bevacizumab before surgery can shrink rectal tumors and improve outcomes. It is designed for people with locally advanced rectal cancer that has not spread to distant organs, and the treatment is given as a first step before the main surgery.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.